| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 273 | 2025 | 570 | 42.290 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 83 | 2025 | 100 | 18.380 |
Why?
|
| Lung | 104 | 2024 | 842 | 8.090 |
Why?
|
| Lung Diseases, Interstitial | 44 | 2024 | 94 | 7.410 |
Why?
|
| Pulmonary Emphysema | 48 | 2024 | 87 | 7.350 |
Why?
|
| Bronchodilator Agents | 49 | 2025 | 97 | 7.180 |
Why?
|
| Forced Expiratory Volume | 74 | 2025 | 150 | 5.270 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 14 | 2023 | 19 | 4.520 |
Why?
|
| Disease Progression | 74 | 2025 | 1054 | 4.380 |
Why?
|
| Chlorobenzenes | 17 | 2025 | 18 | 4.160 |
Why?
|
| Humans | 461 | 2025 | 60122 | 4.110 |
Why?
|
| Adrenal Cortex Hormones | 28 | 2023 | 157 | 3.930 |
Why?
|
| Pulmonary Fibrosis | 29 | 2025 | 53 | 3.780 |
Why?
|
| Muscarinic Antagonists | 10 | 2021 | 26 | 3.760 |
Why?
|
| Tomography, X-Ray Computed | 66 | 2024 | 1481 | 3.670 |
Why?
|
| Benzyl Alcohols | 17 | 2025 | 19 | 3.620 |
Why?
|
| Double-Blind Method | 44 | 2025 | 681 | 3.470 |
Why?
|
| Smoking | 52 | 2025 | 835 | 3.430 |
Why?
|
| Middle Aged | 225 | 2025 | 16546 | 3.300 |
Why?
|
| Aged | 209 | 2025 | 13589 | 3.300 |
Why?
|
| Quality of Life | 50 | 2025 | 1140 | 3.110 |
Why?
|
| Male | 258 | 2025 | 27976 | 3.030 |
Why?
|
| Severity of Illness Index | 65 | 2025 | 1471 | 2.920 |
Why?
|
| Biomarkers | 57 | 2025 | 1213 | 2.920 |
Why?
|
| Respiratory Function Tests | 51 | 2023 | 165 | 2.920 |
Why?
|
| Female | 261 | 2025 | 31245 | 2.870 |
Why?
|
| Vital Capacity | 39 | 2025 | 73 | 2.820 |
Why?
|
| Spirometry | 44 | 2025 | 94 | 2.810 |
Why?
|
| Androstadienes | 17 | 2025 | 30 | 2.690 |
Why?
|
| Precision Medicine | 10 | 2024 | 105 | 2.640 |
Why?
|
| Quinuclidines | 12 | 2025 | 21 | 2.630 |
Why?
|
| Bronchitis, Chronic | 9 | 2023 | 13 | 2.330 |
Why?
|
| Azithromycin | 10 | 2021 | 27 | 2.180 |
Why?
|
| Microbiota | 14 | 2024 | 104 | 2.100 |
Why?
|
| Pneumonectomy | 18 | 2012 | 84 | 2.050 |
Why?
|
| Periodicals as Topic | 6 | 2022 | 175 | 2.010 |
Why?
|
| Glucocorticoids | 5 | 2022 | 172 | 1.990 |
Why?
|
| Administration, Inhalation | 29 | 2025 | 111 | 1.980 |
Why?
|
| Anti-Bacterial Agents | 21 | 2024 | 735 | 1.950 |
Why?
|
| Asthma | 16 | 2023 | 423 | 1.890 |
Why?
|
| Emphysema | 13 | 2024 | 30 | 1.880 |
Why?
|
| Budesonide | 4 | 2025 | 10 | 1.870 |
Why?
|
| Pulmonary Medicine | 7 | 2022 | 36 | 1.850 |
Why?
|
| Glycopyrrolate | 4 | 2025 | 9 | 1.770 |
Why?
|
| Drug Therapy, Combination | 21 | 2025 | 435 | 1.730 |
Why?
|
| Clinical Trials as Topic | 14 | 2024 | 443 | 1.710 |
Why?
|
| Lung Transplantation | 17 | 2024 | 48 | 1.710 |
Why?
|
| Eosinophils | 8 | 2025 | 53 | 1.680 |
Why?
|
| Indoles | 5 | 2023 | 102 | 1.670 |
Why?
|
| Editorial Policies | 3 | 2022 | 53 | 1.630 |
Why?
|
| Lung Diseases | 15 | 2025 | 166 | 1.590 |
Why?
|
| Treatment Outcome | 52 | 2025 | 5265 | 1.550 |
Why?
|
| Prognosis | 39 | 2025 | 1592 | 1.510 |
Why?
|
| Research Design | 7 | 2022 | 569 | 1.480 |
Why?
|
| Surveys and Questionnaires | 37 | 2023 | 2616 | 1.470 |
Why?
|
| Mortality | 3 | 2021 | 165 | 1.460 |
Why?
|
| Dyspnea | 16 | 2023 | 110 | 1.430 |
Why?
|
| Mass Screening | 7 | 2023 | 662 | 1.410 |
Why?
|
| Smokers | 18 | 2023 | 112 | 1.400 |
Why?
|
| Cohort Studies | 48 | 2025 | 2481 | 1.380 |
Why?
|
| Aged, 80 and over | 56 | 2024 | 5201 | 1.360 |
Why?
|
| Early Diagnosis | 6 | 2024 | 90 | 1.300 |
Why?
|
| Critical Care | 4 | 2022 | 417 | 1.300 |
Why?
|
| Biomedical Research | 8 | 2024 | 253 | 1.280 |
Why?
|
| United States | 54 | 2025 | 7622 | 1.280 |
Why?
|
| Proportional Hazards Models | 28 | 2024 | 679 | 1.240 |
Why?
|
| Respiratory Tract Diseases | 4 | 2023 | 35 | 1.240 |
Why?
|
| Air Pollution | 6 | 2024 | 34 | 1.240 |
Why?
|
| Cardiovascular Diseases | 11 | 2025 | 832 | 1.210 |
Why?
|
| Phenotype | 21 | 2025 | 1157 | 1.190 |
Why?
|
| Fluticasone | 7 | 2022 | 13 | 1.180 |
Why?
|
| Airway Obstruction | 8 | 2022 | 35 | 1.180 |
Why?
|
| Formoterol Fumarate | 3 | 2025 | 5 | 1.170 |
Why?
|
| Predictive Value of Tests | 26 | 2021 | 1035 | 1.170 |
Why?
|
| Respiratory Tract Infections | 4 | 2018 | 79 | 1.160 |
Why?
|
| Aminopyridines | 2 | 2018 | 23 | 1.160 |
Why?
|
| Benzamides | 2 | 2018 | 51 | 1.140 |
Why?
|
| Risk Factors | 44 | 2025 | 5090 | 1.120 |
Why?
|
| Tiotropium Bromide | 5 | 2020 | 14 | 1.090 |
Why?
|
| Adult | 80 | 2025 | 15989 | 1.090 |
Why?
|
| Disease Management | 7 | 2021 | 222 | 1.070 |
Why?
|
| Pyridones | 5 | 2023 | 35 | 1.060 |
Why?
|
| Primary Health Care | 4 | 2024 | 660 | 1.050 |
Why?
|
| Prospective Studies | 38 | 2025 | 3131 | 1.030 |
Why?
|
| Hospitalization | 20 | 2025 | 1302 | 1.020 |
Why?
|
| Exercise Tolerance | 14 | 2024 | 71 | 1.020 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2022 | 685 | 1.000 |
Why?
|
| Societies, Medical | 15 | 2025 | 342 | 1.000 |
Why?
|
| Mucin-5B | 8 | 2024 | 9 | 0.990 |
Why?
|
| RNA, Ribosomal, 16S | 10 | 2024 | 77 | 0.990 |
Why?
|
| Air Pollutants | 5 | 2023 | 84 | 0.990 |
Why?
|
| Respiratory Therapy | 3 | 2021 | 11 | 0.950 |
Why?
|
| Bronchi | 8 | 2021 | 79 | 0.940 |
Why?
|
| Alveolitis, Extrinsic Allergic | 7 | 2021 | 13 | 0.940 |
Why?
|
| Lung Diseases, Obstructive | 4 | 2012 | 20 | 0.930 |
Why?
|
| Patient Advocacy | 2 | 2024 | 32 | 0.920 |
Why?
|
| Metagenome | 4 | 2012 | 17 | 0.910 |
Why?
|
| Endpoint Determination | 3 | 2020 | 24 | 0.900 |
Why?
|
| Eosinophilia | 3 | 2025 | 29 | 0.870 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2024 | 677 | 0.850 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2019 | 171 | 0.830 |
Why?
|
| Proteomics | 8 | 2024 | 264 | 0.820 |
Why?
|
| Health Status | 11 | 2020 | 451 | 0.810 |
Why?
|
| Bronchiolitis Obliterans | 6 | 2014 | 17 | 0.800 |
Why?
|
| Fibrinogen | 4 | 2021 | 31 | 0.800 |
Why?
|
| Macrolides | 6 | 2019 | 38 | 0.800 |
Why?
|
| Sleep Medicine Specialty | 1 | 2022 | 3 | 0.780 |
Why?
|
| Inflammation | 9 | 2024 | 1111 | 0.780 |
Why?
|
| Sputum | 7 | 2024 | 36 | 0.770 |
Why?
|
| Oxygen Inhalation Therapy | 7 | 2021 | 49 | 0.770 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2019 | 202 | 0.760 |
Why?
|
| Bacterial Infections | 4 | 2014 | 137 | 0.750 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2019 | 47 | 0.750 |
Why?
|
| Idiopathic Interstitial Pneumonias | 4 | 2016 | 5 | 0.740 |
Why?
|
| Pneumonia, Bacterial | 5 | 2014 | 87 | 0.730 |
Why?
|
| Sildenafil Citrate | 2 | 2019 | 9 | 0.710 |
Why?
|
| Follow-Up Studies | 28 | 2023 | 2362 | 0.700 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 173 | 0.690 |
Why?
|
| Reproducibility of Results | 15 | 2025 | 1565 | 0.680 |
Why?
|
| Sepsis | 2 | 2023 | 282 | 0.680 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2024 | 20 | 0.680 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2019 | 6 | 0.680 |
Why?
|
| Immunoglobulin G | 6 | 2025 | 449 | 0.670 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2024 | 454 | 0.670 |
Why?
|
| Sex Factors | 10 | 2017 | 971 | 0.660 |
Why?
|
| Diagnosis, Differential | 15 | 2024 | 910 | 0.660 |
Why?
|
| Cholinergic Antagonists | 2 | 2019 | 30 | 0.640 |
Why?
|
| Uteroglobin | 2 | 2019 | 7 | 0.640 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2020 | 119 | 0.640 |
Why?
|
| Social Behavior | 1 | 2020 | 89 | 0.640 |
Why?
|
| Benzoxazines | 1 | 2019 | 9 | 0.640 |
Why?
|
| Sensitivity and Specificity | 15 | 2021 | 1100 | 0.640 |
Why?
|
| Cystic Fibrosis | 4 | 2022 | 108 | 0.630 |
Why?
|
| Cross-Sectional Studies | 20 | 2025 | 2505 | 0.630 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2024 | 325 | 0.630 |
Why?
|
| Pulmonary Artery | 4 | 2024 | 90 | 0.620 |
Why?
|
| Antacids | 2 | 2022 | 13 | 0.610 |
Why?
|
| Enzyme Inhibitors | 3 | 2017 | 346 | 0.600 |
Why?
|
| Patient-Centered Care | 2 | 2021 | 250 | 0.600 |
Why?
|
| Telomere | 5 | 2023 | 48 | 0.600 |
Why?
|
| Nebulizers and Vaporizers | 8 | 2022 | 31 | 0.600 |
Why?
|
| Respiratory Mucosa | 3 | 2021 | 53 | 0.600 |
Why?
|
| Fibroblasts | 12 | 2012 | 370 | 0.600 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 2 | 2019 | 6 | 0.590 |
Why?
|
| Age of Onset | 1 | 2018 | 171 | 0.590 |
Why?
|
| Asymptomatic Diseases | 2 | 2017 | 44 | 0.580 |
Why?
|
| Global Health | 6 | 2021 | 165 | 0.580 |
Why?
|
| Anti-Inflammatory Agents | 7 | 2020 | 161 | 0.570 |
Why?
|
| Survival Analysis | 16 | 2024 | 558 | 0.570 |
Why?
|
| Retrospective Studies | 31 | 2023 | 6148 | 0.560 |
Why?
|
| DNA, Mitochondrial | 3 | 2024 | 78 | 0.560 |
Why?
|
| Exercise Test | 11 | 2017 | 237 | 0.560 |
Why?
|
| Survival Rate | 17 | 2019 | 793 | 0.560 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2016 | 2 | 0.550 |
Why?
|
| DNA, Bacterial | 4 | 2014 | 257 | 0.550 |
Why?
|
| Respiratory Mechanics | 5 | 2015 | 52 | 0.550 |
Why?
|
| Osteopontin | 1 | 2016 | 22 | 0.540 |
Why?
|
| Community-Acquired Infections | 3 | 2004 | 88 | 0.540 |
Why?
|
| Drug Discovery | 1 | 2017 | 92 | 0.540 |
Why?
|
| Peer Review, Research | 3 | 2022 | 46 | 0.540 |
Why?
|
| IgG Deficiency | 3 | 2025 | 4 | 0.540 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2021 | 391 | 0.530 |
Why?
|
| Risk Assessment | 14 | 2020 | 1937 | 0.520 |
Why?
|
| Drug Combinations | 9 | 2022 | 138 | 0.510 |
Why?
|
| Biopsy | 11 | 2022 | 376 | 0.510 |
Why?
|
| Hypertension, Pulmonary | 6 | 2022 | 78 | 0.510 |
Why?
|
| Bronchoalveolar Lavage Fluid | 10 | 2021 | 98 | 0.500 |
Why?
|
| Age Factors | 12 | 2022 | 1527 | 0.500 |
Why?
|
| Patient Outcome Assessment | 4 | 2021 | 55 | 0.500 |
Why?
|
| Patient Selection | 7 | 2019 | 453 | 0.500 |
Why?
|
| Acute Disease | 12 | 2018 | 661 | 0.490 |
Why?
|
| Health Status Disparities | 3 | 2021 | 146 | 0.490 |
Why?
|
| Time Factors | 20 | 2021 | 3618 | 0.480 |
Why?
|
| Bronchitis | 2 | 2005 | 25 | 0.480 |
Why?
|
| Cigarette Smoking | 3 | 2023 | 52 | 0.480 |
Why?
|
| Anti-Infective Agents | 3 | 2024 | 140 | 0.480 |
Why?
|
| Longitudinal Studies | 15 | 2025 | 1237 | 0.470 |
Why?
|
| Heart Diseases | 3 | 2018 | 206 | 0.470 |
Why?
|
| Chronic Disease | 8 | 2025 | 744 | 0.460 |
Why?
|
| Multivariate Analysis | 16 | 2019 | 928 | 0.460 |
Why?
|
| Genome-Wide Association Study | 5 | 2023 | 324 | 0.460 |
Why?
|
| Carbon Monoxide | 7 | 2019 | 59 | 0.450 |
Why?
|
| Scopolamine Derivatives | 2 | 2013 | 12 | 0.450 |
Why?
|
| Immunosuppressive Agents | 5 | 2023 | 304 | 0.450 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2015 | 63 | 0.450 |
Why?
|
| Hypoxia | 2 | 2021 | 109 | 0.440 |
Why?
|
| Congresses as Topic | 1 | 2014 | 74 | 0.440 |
Why?
|
| Indans | 1 | 2013 | 11 | 0.440 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2025 | 225 | 0.440 |
Why?
|
| Health Behavior | 1 | 2017 | 472 | 0.430 |
Why?
|
| Particulate Matter | 5 | 2024 | 59 | 0.430 |
Why?
|
| Quinolones | 1 | 2013 | 27 | 0.430 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2021 | 59 | 0.430 |
Why?
|
| Evidence-Based Medicine | 5 | 2017 | 457 | 0.430 |
Why?
|
| Pneumonia | 3 | 2021 | 272 | 0.430 |
Why?
|
| Ozone | 3 | 2024 | 14 | 0.430 |
Why?
|
| Cause of Death | 4 | 2021 | 205 | 0.410 |
Why?
|
| Primary Prevention | 1 | 2014 | 137 | 0.410 |
Why?
|
| Practice Guidelines as Topic | 8 | 2020 | 712 | 0.410 |
Why?
|
| Biological Products | 2 | 2024 | 95 | 0.410 |
Why?
|
| Telomerase | 2 | 2022 | 30 | 0.400 |
Why?
|
| Incidence | 11 | 2021 | 1266 | 0.400 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2023 | 651 | 0.400 |
Why?
|
| Respiratory System | 3 | 2017 | 42 | 0.400 |
Why?
|
| Cough | 3 | 2023 | 183 | 0.380 |
Why?
|
| Genomics | 3 | 2024 | 314 | 0.380 |
Why?
|
| Genotype | 8 | 2022 | 643 | 0.380 |
Why?
|
| Genetic Markers | 4 | 2022 | 122 | 0.380 |
Why?
|
| Blood Proteins | 4 | 2024 | 71 | 0.370 |
Why?
|
| Walking | 3 | 2013 | 230 | 0.360 |
Why?
|
| Multicenter Studies as Topic | 6 | 2022 | 121 | 0.350 |
Why?
|
| Mucus | 5 | 2022 | 15 | 0.350 |
Why?
|
| Acetylcysteine | 3 | 2022 | 24 | 0.350 |
Why?
|
| Aging | 3 | 2024 | 731 | 0.350 |
Why?
|
| Polymorphism, Genetic | 4 | 2020 | 194 | 0.350 |
Why?
|
| alpha 1-Antitrypsin | 2 | 2022 | 88 | 0.340 |
Why?
|
| ROC Curve | 6 | 2017 | 260 | 0.330 |
Why?
|
| Logistic Models | 12 | 2021 | 1262 | 0.330 |
Why?
|
| Case-Control Studies | 9 | 2023 | 1066 | 0.330 |
Why?
|
| Patients | 2 | 2023 | 103 | 0.320 |
Why?
|
| DNA | 4 | 2021 | 793 | 0.320 |
Why?
|
| International Cooperation | 4 | 2017 | 81 | 0.310 |
Why?
|
| Oxygen | 6 | 2016 | 309 | 0.300 |
Why?
|
| Tobacco Products | 3 | 2023 | 76 | 0.300 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 142 | 0.290 |
Why?
|
| Bronchoscopy | 6 | 2022 | 79 | 0.290 |
Why?
|
| Epithelial Cells | 4 | 2021 | 376 | 0.290 |
Why?
|
| Advisory Committees | 4 | 2023 | 107 | 0.290 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 303 | 0.290 |
Why?
|
| Drug Administration Schedule | 6 | 2018 | 281 | 0.290 |
Why?
|
| Cyclopropanes | 2 | 2018 | 41 | 0.290 |
Why?
|
| Pulmonary Diffusing Capacity | 6 | 2019 | 11 | 0.280 |
Why?
|
| Community Medicine | 1 | 2007 | 6 | 0.280 |
Why?
|
| Mucin 5AC | 3 | 2022 | 9 | 0.280 |
Why?
|
| Respiratory Insufficiency | 2 | 2022 | 155 | 0.270 |
Why?
|
| Depression | 3 | 2022 | 868 | 0.270 |
Why?
|
| Oximetry | 2 | 2025 | 49 | 0.270 |
Why?
|
| Linear Models | 6 | 2024 | 422 | 0.270 |
Why?
|
| Growth Differentiation Factor 15 | 2 | 2017 | 5 | 0.270 |
Why?
|
| Forced Expiratory Flow Rates | 2 | 2020 | 3 | 0.270 |
Why?
|
| Needs Assessment | 3 | 2022 | 192 | 0.270 |
Why?
|
| Internationality | 5 | 2018 | 42 | 0.270 |
Why?
|
| Bacteria | 3 | 2021 | 277 | 0.260 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2022 | 35 | 0.260 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2018 | 639 | 0.260 |
Why?
|
| Smoking Cessation | 2 | 2011 | 538 | 0.260 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 577 | 0.260 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2023 | 75 | 0.260 |
Why?
|
| Cost of Illness | 2 | 2018 | 157 | 0.250 |
Why?
|
| Respiratory System Agents | 3 | 2020 | 6 | 0.250 |
Why?
|
| Prevalence | 6 | 2024 | 1300 | 0.250 |
Why?
|
| Virus Diseases | 2 | 2006 | 112 | 0.250 |
Why?
|
| Comorbidity | 7 | 2019 | 1099 | 0.250 |
Why?
|
| Interleukin-5 | 1 | 2025 | 40 | 0.250 |
Why?
|
| Respiratory Muscles | 3 | 2005 | 10 | 0.240 |
Why?
|
| Patient Admission | 1 | 2007 | 184 | 0.240 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2025 | 3 | 0.240 |
Why?
|
| Myocardial Infarction | 3 | 2025 | 867 | 0.240 |
Why?
|
| Regression Analysis | 8 | 2019 | 486 | 0.240 |
Why?
|
| Lung Injury | 2 | 2019 | 32 | 0.240 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 248 | 0.240 |
Why?
|
| Patient Readmission | 2 | 2019 | 424 | 0.240 |
Why?
|
| Gene Expression Regulation | 3 | 2021 | 1538 | 0.240 |
Why?
|
| Altitude | 1 | 2024 | 14 | 0.240 |
Why?
|
| Coronary Artery Disease | 2 | 2018 | 275 | 0.240 |
Why?
|
| Antiviral Agents | 1 | 2007 | 317 | 0.240 |
Why?
|
| Academic Medical Centers | 1 | 2007 | 317 | 0.240 |
Why?
|
| Analysis of Variance | 6 | 2017 | 576 | 0.230 |
Why?
|
| Referral and Consultation | 3 | 2024 | 409 | 0.230 |
Why?
|
| Phenylpropionates | 2 | 2015 | 9 | 0.230 |
Why?
|
| Pyridazines | 2 | 2015 | 8 | 0.230 |
Why?
|
| Women's Health | 1 | 2007 | 390 | 0.230 |
Why?
|
| Heterozygote | 2 | 2022 | 166 | 0.230 |
Why?
|
| Antioxidants | 2 | 2020 | 248 | 0.230 |
Why?
|
| Lakes | 1 | 2024 | 2 | 0.230 |
Why?
|
| Journal Impact Factor | 2 | 2021 | 17 | 0.230 |
Why?
|
| Trachea | 3 | 2018 | 92 | 0.230 |
Why?
|
| Interleukin-17 | 2 | 2018 | 82 | 0.230 |
Why?
|
| Immunoglobulin E | 3 | 2020 | 85 | 0.230 |
Why?
|
| Bronchioles | 2 | 2023 | 4 | 0.220 |
Why?
|
| Home Care Services | 1 | 2025 | 102 | 0.220 |
Why?
|
| Sinusitis | 1 | 2004 | 27 | 0.220 |
Why?
|
| Symptom Flare Up | 2 | 2020 | 13 | 0.220 |
Why?
|
| Air Pollution, Indoor | 1 | 2023 | 35 | 0.220 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 332 | 0.220 |
Why?
|
| Pseudomonas Infections | 1 | 2023 | 52 | 0.220 |
Why?
|
| Radiography, Thoracic | 3 | 2018 | 102 | 0.220 |
Why?
|
| Organizational Objectives | 2 | 2021 | 58 | 0.220 |
Why?
|
| Electrocardiography | 2 | 2025 | 527 | 0.220 |
Why?
|
| Matrix Metalloproteinase 12 | 2 | 2013 | 3 | 0.220 |
Why?
|
| Leukocyte Count | 5 | 2022 | 94 | 0.210 |
Why?
|
| Streptococcus pneumoniae | 2 | 2009 | 58 | 0.210 |
Why?
|
| Data Accuracy | 1 | 2023 | 27 | 0.210 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2024 | 113 | 0.210 |
Why?
|
| Collagen Diseases | 1 | 2003 | 4 | 0.210 |
Why?
|
| Walk Test | 2 | 2021 | 7 | 0.210 |
Why?
|
| Pulmonary Alveoli | 3 | 2019 | 44 | 0.210 |
Why?
|
| Elastin | 2 | 2013 | 10 | 0.210 |
Why?
|
| Cytokines | 4 | 2014 | 911 | 0.210 |
Why?
|
| Algorithms | 7 | 2019 | 1002 | 0.210 |
Why?
|
| Machine Learning | 1 | 2024 | 150 | 0.210 |
Why?
|
| Marijuana Smoking | 1 | 2022 | 16 | 0.200 |
Why?
|
| Environmental Pollutants | 1 | 2023 | 92 | 0.200 |
Why?
|
| Pneumococcal Vaccines | 3 | 2012 | 20 | 0.200 |
Why?
|
| Rhinovirus | 2 | 2013 | 4 | 0.200 |
Why?
|
| History, 21st Century | 3 | 2018 | 166 | 0.200 |
Why?
|
| Scleroderma, Systemic | 1 | 2022 | 14 | 0.200 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 419 | 0.200 |
Why?
|
| Europe | 6 | 2023 | 184 | 0.200 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 215 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2013 | 448 | 0.200 |
Why?
|
| Diagnostic Errors | 1 | 2023 | 98 | 0.200 |
Why?
|
| History, 20th Century | 3 | 2018 | 230 | 0.190 |
Why?
|
| Gender Identity | 2 | 2020 | 61 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2015 | 621 | 0.190 |
Why?
|
| Respiration Disorders | 1 | 2021 | 21 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 11 | 0.190 |
Why?
|
| Social Segregation | 1 | 2021 | 10 | 0.190 |
Why?
|
| Gene Expression | 4 | 2021 | 807 | 0.190 |
Why?
|
| Health Surveys | 1 | 2023 | 311 | 0.190 |
Why?
|
| Avoidance Learning | 1 | 2021 | 22 | 0.190 |
Why?
|
| Transcriptome | 2 | 2021 | 337 | 0.190 |
Why?
|
| NADH Dehydrogenase | 1 | 2021 | 5 | 0.190 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2002 | 53 | 0.190 |
Why?
|
| Child Health | 1 | 2021 | 28 | 0.190 |
Why?
|
| Sleep Wake Disorders | 1 | 2022 | 69 | 0.190 |
Why?
|
| Nursing Research | 1 | 2021 | 41 | 0.180 |
Why?
|
| Network Meta-Analysis | 1 | 2020 | 12 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 213 | 0.180 |
Why?
|
| Goblet Cells | 1 | 2020 | 8 | 0.180 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2017 | 108 | 0.180 |
Why?
|
| Exercise | 4 | 2016 | 918 | 0.180 |
Why?
|
| Antigens | 1 | 2021 | 146 | 0.180 |
Why?
|
| Recovery of Function | 2 | 2020 | 267 | 0.180 |
Why?
|
| Syndrome | 3 | 2022 | 173 | 0.180 |
Why?
|
| Clinical Deterioration | 1 | 2020 | 3 | 0.180 |
Why?
|
| Iron-Binding Proteins | 1 | 2020 | 8 | 0.180 |
Why?
|
| Urban Population | 1 | 2021 | 185 | 0.180 |
Why?
|
| Anniversaries and Special Events | 2 | 2017 | 14 | 0.180 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2020 | 8 | 0.180 |
Why?
|
| Agammaglobulinemia | 1 | 2020 | 8 | 0.180 |
Why?
|
| Physicians | 2 | 2021 | 442 | 0.180 |
Why?
|
| Status Asthmaticus | 1 | 2020 | 7 | 0.180 |
Why?
|
| Pulse Wave Analysis | 1 | 2020 | 10 | 0.180 |
Why?
|
| Albuterol | 3 | 2009 | 20 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2018 | 125 | 0.170 |
Why?
|
| Vascular Stiffness | 1 | 2020 | 14 | 0.170 |
Why?
|
| Morbidity | 4 | 2023 | 110 | 0.170 |
Why?
|
| Quercetin | 1 | 2020 | 24 | 0.170 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2019 | 4 | 0.170 |
Why?
|
| Drug Resistance | 2 | 2018 | 92 | 0.170 |
Why?
|
| Metoprolol | 1 | 2019 | 11 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 157 | 0.170 |
Why?
|
| Endothelial Cells | 1 | 2021 | 177 | 0.170 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2018 | 149 | 0.170 |
Why?
|
| Peak Expiratory Flow Rate | 2 | 2017 | 8 | 0.170 |
Why?
|
| Macrophages, Alveolar | 2 | 2013 | 59 | 0.170 |
Why?
|
| Medical Records | 2 | 2018 | 139 | 0.170 |
Why?
|
| X-Ray Microtomography | 1 | 2019 | 26 | 0.170 |
Why?
|
| Respiratory Paralysis | 1 | 1999 | 3 | 0.170 |
Why?
|
| Iron | 1 | 2020 | 139 | 0.170 |
Why?
|
| Risk | 5 | 2019 | 377 | 0.170 |
Why?
|
| Arm | 1 | 1999 | 38 | 0.160 |
Why?
|
| Animals | 19 | 2021 | 19749 | 0.160 |
Why?
|
| Standard of Care | 1 | 2019 | 27 | 0.160 |
Why?
|
| Drug Approval | 1 | 2019 | 27 | 0.160 |
Why?
|
| Health Services Accessibility | 4 | 2024 | 546 | 0.160 |
Why?
|
| Guideline Adherence | 2 | 2019 | 298 | 0.160 |
Why?
|
| Bronchoalveolar Lavage | 4 | 2023 | 13 | 0.160 |
Why?
|
| Drug Interactions | 1 | 2019 | 113 | 0.160 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 272 | 0.160 |
Why?
|
| Sarcoidosis, Pulmonary | 3 | 2015 | 13 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 4 | 2022 | 854 | 0.160 |
Why?
|
| Emergency Service, Hospital | 1 | 2007 | 1038 | 0.160 |
Why?
|
| Pulmonary Ventilation | 2 | 2009 | 36 | 0.150 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 203 | 0.150 |
Why?
|
| Body Mass Index | 4 | 2016 | 893 | 0.150 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2022 | 325 | 0.150 |
Why?
|
| Vascular Calcification | 1 | 2018 | 21 | 0.150 |
Why?
|
| Weight Gain | 1 | 1999 | 163 | 0.150 |
Why?
|
| Flow Cytometry | 7 | 2019 | 636 | 0.150 |
Why?
|
| Health Status Indicators | 2 | 2018 | 97 | 0.150 |
Why?
|
| Amino Acids | 1 | 2019 | 139 | 0.150 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2018 | 29 | 0.150 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 52 | 0.150 |
Why?
|
| Fibroblast Growth Factor 10 | 1 | 2018 | 2 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2018 | 240 | 0.150 |
Why?
|
| Lung Diseases, Fungal | 1 | 1998 | 31 | 0.150 |
Why?
|
| Social Support | 1 | 2021 | 366 | 0.150 |
Why?
|
| Pneumococcal Infections | 2 | 2012 | 36 | 0.150 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2015 | 24 | 0.150 |
Why?
|
| Transforming Growth Factor beta1 | 5 | 2009 | 53 | 0.150 |
Why?
|
| Cellular Senescence | 1 | 2018 | 106 | 0.150 |
Why?
|
| Protein Kinases | 1 | 2018 | 139 | 0.150 |
Why?
|
| Bacteriological Techniques | 2 | 2014 | 28 | 0.140 |
Why?
|
| Extracellular Matrix | 3 | 2014 | 131 | 0.140 |
Why?
|
| Gastroesophageal Reflux | 2 | 2017 | 78 | 0.140 |
Why?
|
| Mucins | 1 | 2017 | 25 | 0.140 |
Why?
|
| Immunoglobulin A | 1 | 2018 | 93 | 0.140 |
Why?
|
| Mice | 14 | 2021 | 10331 | 0.140 |
Why?
|
| Postoperative Complications | 4 | 2014 | 1175 | 0.140 |
Why?
|
| Early Medical Intervention | 1 | 2017 | 17 | 0.140 |
Why?
|
| Parenchymal Tissue | 1 | 2016 | 4 | 0.140 |
Why?
|
| Helicobacter Infections | 1 | 2017 | 56 | 0.140 |
Why?
|
| Anemia | 1 | 2018 | 119 | 0.140 |
Why?
|
| Helicobacter pylori | 1 | 2017 | 59 | 0.140 |
Why?
|
| Multidetector Computed Tomography | 1 | 2016 | 20 | 0.130 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 21 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2018 | 353 | 0.130 |
Why?
|
| Antibodies, Neutralizing | 2 | 2015 | 191 | 0.130 |
Why?
|
| Fund Raising | 1 | 2016 | 7 | 0.130 |
Why?
|
| Tobacco Use Disorder | 1 | 2019 | 245 | 0.130 |
Why?
|
| Area Under Curve | 3 | 2016 | 125 | 0.130 |
Why?
|
| Bronchiolitis | 2 | 2008 | 17 | 0.130 |
Why?
|
| Genetic Variation | 2 | 2021 | 366 | 0.130 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 51 | 0.130 |
Why?
|
| Proteome | 1 | 2017 | 142 | 0.130 |
Why?
|
| Down-Regulation | 2 | 2017 | 305 | 0.130 |
Why?
|
| Immunity, Innate | 2 | 2023 | 766 | 0.130 |
Why?
|
| Lung Volume Measurements | 3 | 2016 | 15 | 0.130 |
Why?
|
| Peptide Hydrolases | 1 | 2016 | 80 | 0.130 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 233 | 0.130 |
Why?
|
| Oxidative Stress | 4 | 2020 | 282 | 0.130 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 54 | 0.130 |
Why?
|
| Consensus | 4 | 2018 | 199 | 0.130 |
Why?
|
| Catecholamines | 1 | 2015 | 31 | 0.120 |
Why?
|
| Ankyrin Repeat | 1 | 2015 | 1 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2015 | 10 | 0.120 |
Why?
|
| Ofloxacin | 2 | 2005 | 7 | 0.120 |
Why?
|
| Treatment Failure | 4 | 2019 | 189 | 0.120 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2015 | 14 | 0.120 |
Why?
|
| Levofloxacin | 2 | 2005 | 11 | 0.120 |
Why?
|
| Interleukin-15 | 2 | 2017 | 22 | 0.120 |
Why?
|
| Epitopes | 2 | 2013 | 295 | 0.120 |
Why?
|
| Probability | 3 | 2022 | 173 | 0.120 |
Why?
|
| Th2 Cells | 1 | 2015 | 98 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2014 | 4 | 0.120 |
Why?
|
| Subtraction Technique | 1 | 2014 | 22 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2012 | 743 | 0.120 |
Why?
|
| Informatics | 1 | 2014 | 10 | 0.120 |
Why?
|
| Mexico | 1 | 2014 | 42 | 0.120 |
Why?
|
| CD56 Antigen | 1 | 2014 | 15 | 0.120 |
Why?
|
| Republic of Korea | 1 | 2014 | 28 | 0.120 |
Why?
|
| Pattern Recognition, Automated | 1 | 2014 | 61 | 0.120 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 116 | 0.120 |
Why?
|
| Pseudomonas | 1 | 2014 | 7 | 0.120 |
Why?
|
| United Kingdom | 1 | 2014 | 70 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 29 | 0.110 |
Why?
|
| Staphylococcus | 1 | 2014 | 16 | 0.110 |
Why?
|
| Streptococcus | 1 | 2014 | 17 | 0.110 |
Why?
|
| Nitrogen Dioxide | 2 | 2024 | 8 | 0.110 |
Why?
|
| Psychometrics | 1 | 2016 | 359 | 0.110 |
Why?
|
| Simvastatin | 1 | 2014 | 28 | 0.110 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2014 | 75 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2006 | 854 | 0.110 |
Why?
|
| Biopsy, Needle | 2 | 2006 | 129 | 0.110 |
Why?
|
| Specimen Handling | 1 | 2014 | 57 | 0.110 |
Why?
|
| Diagnostic Techniques, Respiratory System | 1 | 2014 | 1 | 0.110 |
Why?
|
| Collagen Type IV | 1 | 2013 | 3 | 0.110 |
Why?
|
| Edetic Acid | 1 | 2014 | 21 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2014 | 57 | 0.110 |
Why?
|
| Culture Techniques | 1 | 2013 | 12 | 0.110 |
Why?
|
| Information Seeking Behavior | 1 | 2014 | 36 | 0.110 |
Why?
|
| Picornaviridae Infections | 1 | 2013 | 2 | 0.110 |
Why?
|
| Serum | 1 | 2014 | 30 | 0.110 |
Why?
|
| Mental Recall | 1 | 2014 | 94 | 0.110 |
Why?
|
| Basement Membrane | 1 | 2013 | 25 | 0.110 |
Why?
|
| Models, Organizational | 1 | 2014 | 93 | 0.110 |
Why?
|
| Contraindications | 3 | 2006 | 46 | 0.110 |
Why?
|
| Plasma | 1 | 2014 | 34 | 0.110 |
Why?
|
| Total Lung Capacity | 3 | 2011 | 9 | 0.110 |
Why?
|
| Sex Distribution | 3 | 2012 | 255 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 7 | 2021 | 3220 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2014 | 169 | 0.110 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2013 | 7 | 0.110 |
Why?
|
| Endothelin A Receptor Antagonists | 1 | 2013 | 1 | 0.110 |
Why?
|
| Disability Evaluation | 1 | 2015 | 217 | 0.110 |
Why?
|
| Oxygen Consumption | 2 | 2011 | 203 | 0.110 |
Why?
|
| C-Reactive Protein | 3 | 2019 | 168 | 0.110 |
Why?
|
| Sulfones | 1 | 2013 | 37 | 0.110 |
Why?
|
| Poisson Distribution | 2 | 2010 | 52 | 0.110 |
Why?
|
| Mannose-Binding Lectin | 1 | 2012 | 3 | 0.100 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 61 | 0.100 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2013 | 67 | 0.100 |
Why?
|
| Autoantigens | 1 | 2013 | 125 | 0.100 |
Why?
|
| Age Distribution | 2 | 2007 | 262 | 0.100 |
Why?
|
| Tomography, Emission-Computed | 1 | 2012 | 38 | 0.100 |
Why?
|
| Piperazines | 1 | 2013 | 81 | 0.100 |
Why?
|
| Disease Models, Animal | 6 | 2021 | 2078 | 0.100 |
Why?
|
| Postoperative Period | 3 | 2006 | 127 | 0.100 |
Why?
|
| RNA, Double-Stranded | 1 | 2013 | 108 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 3 | 2018 | 661 | 0.100 |
Why?
|
| Radiography | 2 | 2004 | 514 | 0.100 |
Why?
|
| Child | 4 | 2023 | 4332 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 88 | 0.100 |
Why?
|
| Proteolysis | 1 | 2013 | 137 | 0.100 |
Why?
|
| Cells, Cultured | 6 | 2014 | 2101 | 0.100 |
Why?
|
| Bayes Theorem | 2 | 2022 | 106 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 2013 | 160 | 0.100 |
Why?
|
| Forecasting | 2 | 2019 | 221 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 4 | 2014 | 397 | 0.100 |
Why?
|
| Young Adult | 6 | 2024 | 4398 | 0.100 |
Why?
|
| Monitoring, Physiologic | 2 | 2025 | 151 | 0.100 |
Why?
|
| Self Report | 1 | 2014 | 369 | 0.100 |
Why?
|
| Aorta | 1 | 2012 | 106 | 0.100 |
Why?
|
| Ontario | 1 | 2011 | 44 | 0.100 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2013 | 148 | 0.100 |
Why?
|
| Self-Assessment | 2 | 2010 | 58 | 0.090 |
Why?
|
| Molecular Epidemiology | 2 | 2022 | 26 | 0.090 |
Why?
|
| Environmental Exposure | 2 | 2024 | 212 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2025 | 84 | 0.090 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2011 | 34 | 0.090 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2011 | 6 | 0.090 |
Why?
|
| Hydroxyurea | 1 | 2011 | 22 | 0.090 |
Why?
|
| Health | 1 | 2011 | 32 | 0.090 |
Why?
|
| Leukocytes | 2 | 2023 | 99 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 118 | 0.090 |
Why?
|
| Toll-Like Receptors | 1 | 2013 | 434 | 0.090 |
Why?
|
| Pleural Diseases | 2 | 2005 | 9 | 0.090 |
Why?
|
| Decision Making | 2 | 2018 | 394 | 0.090 |
Why?
|
| Social Class | 2 | 2021 | 126 | 0.090 |
Why?
|
| Doxycycline | 2 | 2015 | 41 | 0.090 |
Why?
|
| Residual Volume | 2 | 2009 | 3 | 0.090 |
Why?
|
| Epoxide Hydrolases | 2 | 2007 | 5 | 0.090 |
Why?
|
| Internet | 1 | 2014 | 463 | 0.090 |
Why?
|
| Biological Variation, Population | 2 | 2020 | 9 | 0.090 |
Why?
|
| Hemodynamics | 1 | 2011 | 236 | 0.090 |
Why?
|
| Radiology | 1 | 2014 | 234 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 524 | 0.090 |
Why?
|
| Metabolomics | 2 | 2021 | 53 | 0.090 |
Why?
|
| Interleukin-18 | 1 | 2010 | 74 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2022 | 856 | 0.080 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2009 | 41 | 0.080 |
Why?
|
| Sickness Impact Profile | 1 | 2009 | 46 | 0.080 |
Why?
|
| Pulmonary Veins | 1 | 2009 | 36 | 0.080 |
Why?
|
| Poverty | 2 | 2022 | 293 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 5 | 2012 | 161 | 0.080 |
Why?
|
| NADPH Oxidases | 1 | 2009 | 64 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2012 | 306 | 0.080 |
Why?
|
| Patient Compliance | 3 | 2019 | 373 | 0.080 |
Why?
|
| Michigan | 2 | 2021 | 39 | 0.080 |
Why?
|
| Hydrogen Peroxide | 2 | 2009 | 75 | 0.080 |
Why?
|
| Mass Spectrometry | 3 | 2017 | 288 | 0.080 |
Why?
|
| Apoptosis | 1 | 2014 | 1040 | 0.080 |
Why?
|
| Phylogeny | 2 | 2024 | 334 | 0.080 |
Why?
|
| Motor Activity | 1 | 2012 | 343 | 0.080 |
Why?
|
| Mesoderm | 1 | 2009 | 84 | 0.080 |
Why?
|
| Quantitative Trait Loci | 2 | 2021 | 71 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2021 | 365 | 0.080 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 157 | 0.080 |
Why?
|
| Vaccination | 1 | 2011 | 344 | 0.080 |
Why?
|
| Health Education | 2 | 2007 | 184 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 237 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2006 | 257 | 0.080 |
Why?
|
| Observer Variation | 2 | 2010 | 203 | 0.080 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2006 | 15 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 2 | 2019 | 30 | 0.080 |
Why?
|
| Bronchiectasis | 1 | 2008 | 8 | 0.070 |
Why?
|
| Inflammasomes | 1 | 2012 | 333 | 0.070 |
Why?
|
| Fibronectins | 1 | 2007 | 41 | 0.070 |
Why?
|
| Symptom Assessment | 2 | 2019 | 40 | 0.070 |
Why?
|
| Dinoprostone | 1 | 2007 | 44 | 0.070 |
Why?
|
| Graft Survival | 2 | 2006 | 279 | 0.070 |
Why?
|
| Antigens, CD | 4 | 2010 | 344 | 0.070 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2007 | 5 | 0.070 |
Why?
|
| Cell Differentiation | 3 | 2009 | 1297 | 0.070 |
Why?
|
| Steroids | 1 | 2007 | 55 | 0.070 |
Why?
|
| Life Expectancy | 1 | 2007 | 34 | 0.070 |
Why?
|
| Pandemics | 2 | 2024 | 629 | 0.070 |
Why?
|
| Graft Rejection | 2 | 2006 | 264 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2012 | 704 | 0.070 |
Why?
|
| Respiration | 2 | 2018 | 88 | 0.070 |
Why?
|
| Palliative Care | 1 | 2009 | 215 | 0.070 |
Why?
|
| Anxiety | 1 | 2010 | 400 | 0.070 |
Why?
|
| DNA, Viral | 1 | 2007 | 228 | 0.070 |
Why?
|
| Qualitative Research | 2 | 2024 | 633 | 0.070 |
Why?
|
| Awareness | 1 | 2007 | 74 | 0.070 |
Why?
|
| Interviews as Topic | 2 | 2024 | 495 | 0.070 |
Why?
|
| Interleukin-13 | 1 | 2006 | 35 | 0.070 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2006 | 9 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2009 | 508 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2015 | 1849 | 0.070 |
Why?
|
| Microspheres | 1 | 2005 | 55 | 0.060 |
Why?
|
| RNA, Messenger | 5 | 2010 | 1469 | 0.060 |
Why?
|
| Latin America | 2 | 2018 | 15 | 0.060 |
Why?
|
| Japan | 2 | 2018 | 57 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2025 | 71 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2005 | 83 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2005 | 59 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 792 | 0.060 |
Why?
|
| Scleroderma, Diffuse | 1 | 2004 | 2 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 806 | 0.060 |
Why?
|
| Nitrogen Oxides | 1 | 2024 | 8 | 0.060 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2005 | 27 | 0.060 |
Why?
|
| Connective Tissue Diseases | 1 | 2024 | 10 | 0.060 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2004 | 5 | 0.060 |
Why?
|
| Aza Compounds | 1 | 2004 | 3 | 0.060 |
Why?
|
| Naphthyridines | 1 | 2004 | 6 | 0.060 |
Why?
|
| Receptors, Chemokine | 1 | 2004 | 32 | 0.060 |
Why?
|
| Chemokines, CC | 1 | 2004 | 27 | 0.060 |
Why?
|
| Quinolines | 1 | 2004 | 39 | 0.060 |
Why?
|
| Mouth | 1 | 2024 | 32 | 0.060 |
Why?
|
| Hepatorenal Syndrome | 1 | 2003 | 2 | 0.060 |
Why?
|
| Fluoroquinolones | 1 | 2004 | 30 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 424 | 0.060 |
Why?
|
| Liver Failure | 1 | 2003 | 16 | 0.060 |
Why?
|
| Ascites | 1 | 2003 | 21 | 0.060 |
Why?
|
| Hepatic Encephalopathy | 1 | 2003 | 8 | 0.060 |
Why?
|
| Bleomycin | 3 | 2012 | 32 | 0.060 |
Why?
|
| Oxyhemoglobins | 1 | 2003 | 9 | 0.050 |
Why?
|
| Alarmins | 1 | 2023 | 4 | 0.050 |
Why?
|
| Cities | 1 | 2023 | 25 | 0.050 |
Why?
|
| Unsupervised Machine Learning | 1 | 2023 | 2 | 0.050 |
Why?
|
| Cell Death | 1 | 2005 | 272 | 0.050 |
Why?
|
| Proprotein Convertases | 1 | 2023 | 6 | 0.050 |
Why?
|
| Societies | 1 | 2023 | 22 | 0.050 |
Why?
|
| Family Characteristics | 1 | 2023 | 44 | 0.050 |
Why?
|
| Heart-Lung Transplantation | 1 | 2003 | 4 | 0.050 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2003 | 15 | 0.050 |
Why?
|
| Cotinine | 1 | 2022 | 18 | 0.050 |
Why?
|
| Soot | 1 | 2022 | 9 | 0.050 |
Why?
|
| Gastroenterology | 1 | 2003 | 53 | 0.050 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2022 | 8 | 0.050 |
Why?
|
| Occupational Diseases | 1 | 2005 | 266 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2025 | 774 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2023 | 82 | 0.050 |
Why?
|
| Fibrosis | 3 | 2010 | 152 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 104 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 194 | 0.050 |
Why?
|
| Thorax | 1 | 2022 | 33 | 0.050 |
Why?
|
| Carbon | 1 | 2022 | 47 | 0.050 |
Why?
|
| Sclerosis | 1 | 2022 | 7 | 0.050 |
Why?
|
| Organ Dysfunction Scores | 1 | 2022 | 18 | 0.050 |
Why?
|
| Hemorrhage | 2 | 2022 | 272 | 0.050 |
Why?
|
| Ion Transport | 1 | 2022 | 19 | 0.050 |
Why?
|
| Exome | 1 | 2022 | 73 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2022 | 113 | 0.050 |
Why?
|
| Adenosine | 1 | 2022 | 69 | 0.050 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2021 | 4 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 23 | 0.050 |
Why?
|
| Lymphangioleiomyomatosis | 2 | 2015 | 3 | 0.050 |
Why?
|
| Diaphragm | 2 | 1999 | 23 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 209 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 63 | 0.050 |
Why?
|
| Pancreatic Elastase | 1 | 2021 | 31 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 61 | 0.050 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2012 | 6 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 70 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2022 | 198 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 1 | 2021 | 102 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2021 | 137 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2020 | 85 | 0.040 |
Why?
|
| California | 1 | 2021 | 162 | 0.040 |
Why?
|
| Caregivers | 1 | 2023 | 232 | 0.040 |
Why?
|
| Ferritins | 1 | 2020 | 32 | 0.040 |
Why?
|
| Actins | 3 | 2007 | 258 | 0.040 |
Why?
|
| Maximal Midexpiratory Flow Rate | 1 | 2020 | 2 | 0.040 |
Why?
|
| Isoelectric Focusing | 1 | 2020 | 11 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2023 | 242 | 0.040 |
Why?
|
| Models, Animal | 1 | 2021 | 222 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 96 | 0.040 |
Why?
|
| Linkage Disequilibrium | 2 | 2013 | 46 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 2020 | 57 | 0.040 |
Why?
|
| Protein Interaction Mapping | 1 | 2020 | 71 | 0.040 |
Why?
|
| Cell Line | 3 | 2013 | 2018 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2021 | 194 | 0.040 |
Why?
|
| Muscle, Smooth | 2 | 2015 | 138 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2001 | 177 | 0.040 |
Why?
|
| Airway Remodeling | 1 | 2019 | 7 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2015 | 129 | 0.040 |
Why?
|
| Obesity | 2 | 2021 | 1191 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2010 | 106 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2021 | 229 | 0.040 |
Why?
|
| Antifibrinolytic Agents | 1 | 2019 | 16 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2021 | 273 | 0.040 |
Why?
|
| Isoleucine | 1 | 2019 | 9 | 0.040 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2019 | 13 | 0.040 |
Why?
|
| Azathioprine | 1 | 2019 | 23 | 0.040 |
Why?
|
| Valine | 1 | 2019 | 30 | 0.040 |
Why?
|
| Metered Dose Inhalers | 1 | 2019 | 5 | 0.040 |
Why?
|
| Lectins, C-Type | 2 | 2010 | 78 | 0.040 |
Why?
|
| Germ-Free Life | 1 | 2019 | 8 | 0.040 |
Why?
|
| Tryptophan | 1 | 2019 | 55 | 0.040 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2019 | 19 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2014 | 498 | 0.040 |
Why?
|
| Ischemic Attack, Transient | 1 | 2020 | 91 | 0.040 |
Why?
|
| Prednisone | 1 | 2019 | 80 | 0.040 |
Why?
|
| Leucine | 1 | 2019 | 61 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 405 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 295 | 0.040 |
Why?
|
| Carbon Dioxide | 1 | 1999 | 78 | 0.040 |
Why?
|
| Wound Healing | 2 | 2012 | 177 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2019 | 23 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 61 | 0.040 |
Why?
|
| Telomere Homeostasis | 1 | 2018 | 4 | 0.040 |
Why?
|
| Evidence-Based Practice | 1 | 2019 | 82 | 0.040 |
Why?
|
| Tomography, Spiral Computed | 1 | 2018 | 21 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 17 | 0.040 |
Why?
|
| Occupational Health | 1 | 2020 | 186 | 0.040 |
Why?
|
| Psoriasis | 1 | 2018 | 51 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 164 | 0.040 |
Why?
|
| Chest Pain | 1 | 2019 | 84 | 0.040 |
Why?
|
| Diffusion | 2 | 2010 | 84 | 0.040 |
Why?
|
| Medicare | 1 | 2022 | 603 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2015 | 584 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2005 | 2892 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 712 | 0.040 |
Why?
|
| Carboxyhemoglobin | 1 | 2017 | 13 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 202 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2017 | 33 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 193 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 170 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2017 | 33 | 0.040 |
Why?
|
| Patient Safety | 1 | 2020 | 244 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2020 | 249 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2017 | 59 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2020 | 475 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2017 | 35 | 0.040 |
Why?
|
| Reference Values | 1 | 2018 | 322 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2017 | 83 | 0.030 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 191 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2018 | 133 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 531 | 0.030 |
Why?
|
| Causality | 1 | 2017 | 56 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1015 | 0.030 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 2 | 0.030 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2016 | 5 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 1999 | 351 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 249 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 15 | 0.030 |
Why?
|
| North America | 1 | 2016 | 115 | 0.030 |
Why?
|
| Cell Culture Techniques | 2 | 2009 | 179 | 0.030 |
Why?
|
| Cathepsins | 1 | 2016 | 33 | 0.030 |
Why?
|
| Autophagy | 1 | 2018 | 208 | 0.030 |
Why?
|
| Lectins | 1 | 2016 | 38 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2007 | 236 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 184 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 2016 | 91 | 0.030 |
Why?
|
| Belgium | 1 | 2015 | 6 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2016 | 44 | 0.030 |
Why?
|
| Antimetabolites | 1 | 2015 | 17 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 23 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 53 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 423 | 0.030 |
Why?
|
| World Health Organization | 1 | 2015 | 30 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2015 | 21 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 337 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2015 | 10 | 0.030 |
Why?
|
| Canada | 1 | 2015 | 150 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 14 | 0.030 |
Why?
|
| Sirolimus | 1 | 2015 | 77 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 211 | 0.030 |
Why?
|
| Cell Division | 2 | 2007 | 442 | 0.030 |
Why?
|
| Policy Making | 1 | 2015 | 51 | 0.030 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2014 | 7 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 2014 | 29 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2014 | 31 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 125 | 0.030 |
Why?
|
| Adolescent | 2 | 2017 | 5959 | 0.030 |
Why?
|
| Tissue Donors | 2 | 2006 | 133 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2014 | 98 | 0.030 |
Why?
|
| Psychophysiologic Disorders | 1 | 1994 | 7 | 0.030 |
Why?
|
| Carbon Tetrachloride | 1 | 2013 | 9 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 160 | 0.030 |
Why?
|
| Bronchial Hyperreactivity | 1 | 1994 | 29 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 719 | 0.030 |
Why?
|
| Physical Exertion | 1 | 1994 | 78 | 0.030 |
Why?
|
| Physical Fitness | 1 | 1994 | 92 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 334 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 2015 | 254 | 0.030 |
Why?
|
| Placebos | 1 | 2013 | 71 | 0.030 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2013 | 28 | 0.030 |
Why?
|
| Bronchial Diseases | 1 | 1993 | 10 | 0.030 |
Why?
|
| Purines | 1 | 2013 | 38 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 59 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 103 | 0.030 |
Why?
|
| Cecum | 1 | 2012 | 15 | 0.030 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2012 | 8 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 60 | 0.030 |
Why?
|
| Intelligence Tests | 1 | 2012 | 27 | 0.030 |
Why?
|
| Observation | 1 | 2012 | 30 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2012 | 43 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2012 | 31 | 0.030 |
Why?
|
| Aortography | 1 | 2012 | 54 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1994 | 158 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 406 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 237 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 119 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2012 | 253 | 0.020 |
Why?
|
| Lipids | 1 | 2014 | 306 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2012 | 132 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2011 | 21 | 0.020 |
Why?
|
| Perception | 1 | 2012 | 179 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 2011 | 34 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2012 | 472 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 742 | 0.020 |
Why?
|
| Caspase 1 | 1 | 2012 | 110 | 0.020 |
Why?
|
| Monitoring, Ambulatory | 1 | 2012 | 56 | 0.020 |
Why?
|
| Leukotriene E4 | 1 | 2011 | 7 | 0.020 |
Why?
|
| Leukotriene B4 | 1 | 2011 | 13 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 594 | 0.020 |
Why?
|
| Stroke | 1 | 2020 | 1144 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2012 | 252 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2011 | 82 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 600 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2013 | 310 | 0.020 |
Why?
|
| Monocytes | 1 | 2012 | 346 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 876 | 0.020 |
Why?
|
| Common Cold | 1 | 2010 | 8 | 0.020 |
Why?
|
| Echocardiography | 1 | 2013 | 460 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 1914 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 147 | 0.020 |
Why?
|
| NADPH Oxidase 4 | 1 | 2009 | 5 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2012 | 256 | 0.020 |
Why?
|
| Smad3 Protein | 1 | 2009 | 18 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2010 | 144 | 0.020 |
Why?
|
| Proteins | 2 | 2006 | 743 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2011 | 323 | 0.020 |
Why?
|
| Viral Load | 1 | 2010 | 229 | 0.020 |
Why?
|
| Saccharopolyspora | 1 | 2009 | 1 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2009 | 84 | 0.020 |
Why?
|
| Thoracoscopy | 1 | 2009 | 23 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 1580 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 1973 | 0.020 |
Why?
|
| Stem Cells | 1 | 2010 | 258 | 0.020 |
Why?
|
| Rest | 1 | 2008 | 43 | 0.020 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2009 | 56 | 0.020 |
Why?
|
| Focus Groups | 1 | 2010 | 294 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 943 | 0.020 |
Why?
|
| Life Style | 1 | 2010 | 330 | 0.020 |
Why?
|
| Theophylline | 1 | 2007 | 6 | 0.020 |
Why?
|
| Salmeterol Xinafoate | 1 | 2007 | 4 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2009 | 198 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2007 | 38 | 0.020 |
Why?
|
| Connective Tissue Cells | 1 | 2007 | 2 | 0.020 |
Why?
|
| Length of Stay | 1 | 2011 | 781 | 0.020 |
Why?
|
| Donor Selection | 1 | 2006 | 16 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2007 | 143 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 89 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2006 | 104 | 0.020 |
Why?
|
| Waiting Lists | 1 | 2006 | 48 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2007 | 185 | 0.020 |
Why?
|
| Tissue and Organ Procurement | 1 | 2006 | 37 | 0.020 |
Why?
|
| Receptors, Interleukin-13 | 1 | 2006 | 2 | 0.020 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 1 | 2006 | 2 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 2006 | 8 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2007 | 155 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2007 | 88 | 0.020 |
Why?
|
| Receptors, Interleukin | 1 | 2006 | 36 | 0.020 |
Why?
|
| Immunity | 1 | 2007 | 97 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein B | 1 | 2006 | 1 | 0.020 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2006 | 1 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2007 | 230 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 31 | 0.020 |
Why?
|
| Mucociliary Clearance | 1 | 2005 | 6 | 0.020 |
Why?
|
| Collagenases | 1 | 2005 | 14 | 0.020 |
Why?
|
| Catalase | 1 | 2005 | 21 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2005 | 13 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2005 | 98 | 0.020 |
Why?
|
| Muscle Cells | 1 | 2005 | 27 | 0.020 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2005 | 14 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2005 | 94 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 2005 | 60 | 0.010 |
Why?
|
| Relaxin | 1 | 2004 | 2 | 0.010 |
Why?
|
| Molybdenum | 1 | 2004 | 4 | 0.010 |
Why?
|
| Endothelin-1 | 1 | 2004 | 7 | 0.010 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2004 | 6 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2005 | 281 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 218 | 0.010 |
Why?
|
| Chemokine CCL7 | 1 | 2004 | 1 | 0.010 |
Why?
|
| Renin-Angiotensin System | 1 | 2004 | 22 | 0.010 |
Why?
|
| Eicosanoids | 1 | 2004 | 25 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 113 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 44 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2005 | 124 | 0.010 |
Why?
|
| Liver, Artificial | 1 | 2003 | 2 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 969 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 187 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2005 | 280 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 855 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 155 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 316 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 558 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2007 | 1998 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 860 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2003 | 136 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2004 | 550 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 697 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2005 | 448 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2005 | 568 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2003 | 159 | 0.010 |
Why?
|
| HIV Infections | 1 | 2005 | 927 | 0.010 |
Why?
|
| Maximal Expiratory Flow-Volume Curves | 1 | 1993 | 1 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1993 | 111 | 0.010 |
Why?
|